Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Windtree TherapeuticsWINT 3-Year FCF Growth Rate is 77.00% as of Sep. 2025, which is at its 10-year median of 77.00. The stock has 2 warning signs investors should review. Among 1,103 Biotechnology companies, Windtree Therapeutics ranks better than 95.29% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 77.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Windtree Therapeutics was 77.00% per year. The lowest was 77.00% per year. And the median was 77.00% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Windtree Therapeutics 3-Year FCF Growth Rate Related Terms
WINT vs LIPO, ITRMF, IOBTQ: 3-Year FCF Growth Rate Comparison
For the Biotechnology subindustry, Windtree Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windtree Therapeutics 3-Year FCF Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Windtree Therapeutics's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 77.00% mean?
Windtree Therapeutics (WINT) has a 3-Year FCF Growth Rate of 77.00% as of Sep. 2025. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Windtree Therapeutics and its competitors. This is near median its historical median of 77.00. Over the past decade, Windtree Therapeutics' 3-Year FCF Growth Rate has ranged from 77.00 to 77.00. According to the industry distribution chart, Windtree Therapeutics ranks #52 out of 1103 companies in the Biotechnology industry, placing it in the top 4.7%.
Is Windtree Therapeutics' 3-Year FCF Growth Rate too high?
Windtree Therapeutics' current 3-Year FCF Growth Rate of 77.00% is near median its 10-year median of 77.00. Over the past 10 years, this metric has ranged from a low of 77.00 to a high of 77.00. The Biotechnology industry median 3-Year FCF Growth Rate is 19.40. Windtree Therapeutics' value of 77.00% is 296.9% above this industry median. Based on the distribution chart, Windtree Therapeutics ranks #52 out of 1103 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Windtree Therapeutics' 3-Year FCF Growth Rate compare to LIPO and ITRMF?
According to the Biotechnology industry distribution chart, Windtree Therapeutics ranks #52 out of 1103 companies for 3-Year FCF Growth Rate. This places Windtree Therapeutics in the top 5% of its industry — outperforming the majority of peers. The industry median 3-Year FCF Growth Rate is 19.40. Windtree Therapeutics' value of 77.00% is 296.9% above this benchmark. Historically, Windtree Therapeutics' own 3-Year FCF Growth Rate has ranged from 77.00 to 77.00 over the past decade. While the company's 10-year median is 77.00 vs. the industry median of 19.40, Windtree Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Biotechnology company?
The median 3-Year FCF Growth Rate among Biotechnology companies is 19.40, based on 1,103 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windtree Therapeutics's current 3-Year FCF Growth Rate of 77.00% is 296.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Windtree Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year FCF Growth Rate is 19.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windtree Therapeutics's current 3-Year FCF Growth Rate is 77.00%, which is near median its own 10-year median of 77.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windtree Therapeutics stock overvalued right now?
Windtree Therapeutics (WINT) has a current 3-Year FCF Growth Rate of 77.00%. The current 3-Year FCF Growth Rate is 77.00%, which is near median its 10-year median of 77.00 and 296.9% above the Biotechnology industry median of 19.40. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Windtree Therapeutics (WINT), the current 3-Year FCF Growth Rate is 77.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WINT has been successfully added to your 
